Xeris Biopharma (NASDAQ:XERS) Stock Price Target Raised at HC Wainwright

Xeris Biopharma (NASDAQ:XERS) had its price target boosted by HC Wainwright from $10.00 to $18.00 in a research note released on Friday,Benzinga reports. HC Wainwright currently has a buy rating on the stock. HC Wainwright also issued estimates for Xeris Biopharma’s FY2029 earnings at $0.63 EPS.

Several other equities research analysts have also recently issued reports on the stock. Wall Street Zen raised shares of Xeris Biopharma from a “hold” rating to a “buy” rating in a research report on Saturday, September 19th. Barclays raised their price target on Xeris Biopharma from $12.00 to $14.00 and gave the company an “overweight” rating in a research note on Tuesday, October 6th. Leerink Partners lifted their price target on Xeris Biopharma from $12.00 to $16.00 and gave the stock an “outperform” rating in a report on Thursday, September 10th. Finally, Weiss Ratings cut Xeris Biopharma from a “hold (c-)” rating to a “sell (d-)” rating in a research report on Tuesday, August 11th. Four investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $16.20.

Xeris Biopharma Stock Up 16.2%

Shares of XERS stock traded up $2.12 during trading hours on Friday, reaching $15.20. 7,895,311 shares of the stock were exchanged, compared to its average volume of 2,146,978. The business’s fifty day moving average is $9.62 and its two-hundred day moving average is $7.62. The company has a debt-to-equity ratio of 17.00, a current ratio of 1.45 and a quick ratio of 1.02. Xeris Biopharma has a 12-month low of $5.25 and a 12-month high of $15.21. The firm has a market capitalization of $2.77 billion, a P/E ratio of -303.94 and a beta of 0.61.

Xeris Biopharma (NASDAQ:XERS) last issued its quarterly earnings results on Thursday, November 5th. The company reported $0.06 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.03 by $0.03. Xeris Biopharma had a negative net margin of 5.12% and a positive return on equity of 338.21%. The company had revenue of $107.23 million during the quarter, compared to the consensus estimate of $101.68 million. As a group, research analysts expect that Xeris Biopharma will post 0.07 EPS for the current fiscal year.

Insider Activity at Xeris Biopharma

In other Xeris Biopharma news, insider Kevin McCulloch sold 25,000 shares of the business’s stock in a transaction that occurred on Thursday, November 5th. The stock was sold at an average price of $12.49, for a total value of $312,250.00. Following the completion of the sale, the insider owned 1,559,208 shares in the company, valued at approximately $19,474,507.92. The trade was a 1.58% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Beth Hecht sold 25,000 shares of the stock in a transaction that occurred on Monday, November 2nd. The shares were sold at an average price of $10.23, for a total value of $255,750.00. Following the completion of the sale, the insider directly owned 1,086,130 shares of the company’s stock, valued at $11,111,109.90. The trade was a 2.25% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 173,332 shares of company stock valued at $1,721,471 over the last ninety days. Insiders own 4.35% of the company’s stock.

Institutional Trading of Xeris Biopharma

A number of large investors have recently bought and sold shares of the business. BlackRock Inc. acquired a new position in Xeris Biopharma in the second quarter valued at $115,042,000. Wellington Management Group LLP grew its holdings in shares of Xeris Biopharma by 8.9% during the second quarter. Wellington Management Group LLP now owns 2,365,103 shares of the company’s stock worth $18,732,000 after buying an additional 193,749 shares during the last quarter. Legal & General Group Plc purchased a new position in shares of Xeris Biopharma during the second quarter worth about $15,941,000. Parkman Healthcare Partners LLC acquired a new position in Xeris Biopharma in the 2nd quarter valued at about $14,316,000. Finally, Algert Global LLC increased its position in Xeris Biopharma by 50.6% in the 2nd quarter. Algert Global LLC now owns 1,742,942 shares of the company’s stock valued at $13,804,000 after acquiring an additional 585,984 shares during the period. Institutional investors and hedge funds own 42.75% of the company’s stock.

Trending Headlines about Xeris Biopharma

Here are the key news stories impacting Xeris Biopharma this week:

• Positive Sentiment: Q3 results beat expectations: Xeris reported earnings of $0.06 per share versus a $0.03 consensus estimate, while revenue of $107.23 million exceeded forecasts of $101.68 million. The results provide evidence of stronger-than-expected performance. Xeris Biopharma Reports Third Quarter 2026 Financial Results and Business Highlights
• Positive Sentiment: Analysts raised targets: Oppenheimer reaffirmed its “outperform” rating and lifted its target to $21 from $18. HC Wainwright kept a “buy” rating and raised its target to $18 from $10. These revisions suggest greater optimism about Xeris’s prospects. Oppenheimer ratings HC Wainwright ratings
• Positive Sentiment: Recorlev sales outlook: CEO John Shannon reportedly sees the drug approaching $1 billion in annual sales three to four years earlier than previously expected, a potentially meaningful growth driver. CEO comments on Recorlev sales outlook
• Neutral Sentiment: Insider Kevin McCulloch sold 25,000 shares under a pre-arranged Rule 10b5-1 plan, a modest reduction; he retained more than 1.55 million shares. SEC Form 4 filing
• Negative Sentiment: Cautious analyst view: Piper Sandler reaffirmed “neutral” despite raising its target to $12 from $8. That target remains below the share price cited in the report, signaling valuation concerns. Piper Sandler ratings

Xeris Biopharma Company Profile

Xeris Biopharma, Inc is a specialty pharmaceutical company focused on developing and commercializing therapies for patients with endocrinology, gastroenterology and other serious or chronic conditions. The company uses proprietary formulation and delivery technologies designed to make complex therapies more stable, convenient and suitable for self-administration.

Xeris’ commercial portfolio includes Gvoke, a ready-to-use glucagon injection for the treatment of severe hypoglycemia in adults and children with diabetes; Recorlev (levoketoconazole), an oral therapy for endogenous hypercortisolemia associated with endogenous Cushing’s syndrome; and Keveyis (dichlorphenamide), a treatment for primary periodic paralysis.